前往化源商城

904575-33-3 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: 12hLO-f5-genesis-15-1hLO
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION
1; Enzyme; 3 uL; 40 nM ALOX15 (15hLO-1) enzyme solution dispensed in 1536-well Greiner black, clear bottom plates.
2; Compound; 23 nL; compounds and controls were added.
3; Incubate; 15 min; room temperature.
4; Substrate; 1 uL; 50 uM arachidonic acid (final concentration).
5; Incubate; 30 min; room temperature.
6; Reagent; 4 uL; Fe-XO solution was added to each well.
7; Centrifuge; 1000 rpm, 15 sec.
8; Incubation; 30 min; room temperature
9; Detector; absorbance; Read 1 at 405 nm absorbance using ViewLux (PerkinElmer) CCD imager.
10; Detector; absorbance; Read 2 at 573 nm absorbance using ViewLux (PerkinElmer) CCD imager.

NOTES (numbers refer to sequence above)
1; 40 nM ALOX15 (final concentration) in buffer solution (25 mM Hepes, 0.01% Triton X-100, pH 7.5) was dispensed in columns 1, 2, 5 - 48. Column 1 is neutral (100% activity). Buffer only was dispensed in columns 3 and 4 as no enzyme negative controls. The plates were covered with metal lids with gas-exchange holes.
2; Compounds were pin transferred via a Kalypsys Pin Tool (Wako USA) in column 5 - 48. Control compound was transferred in column 2, titration of nordihydroguaiaretic acid (NDGA, Sigma-Aldrich, N5023) with top concentration of 10 mM in DMSO then 1:2 dilution in duplicate. Dilution factor of 23 nL into 4 uL final assay volume.
3; Covered assay plates were incubated for 15 min at room temperature.
4; Substrate was added to start the reaction; 50 uM arachidonic acid (Sigma-Aldrich, St. Louis, MO) was dispensed throughout the plate.
6; Chromogenic detection reagent solution (divalent iron/xylenol orange, Fe-XO) was added to each well: 200 uM xylenol orange, 300 uM ferrous ammonium sulfate prepared freshly in 50 mM sulfuric acid.
9, 10; Two absorbance readouts were obtained at 405 nm and at 573 nm using a ViewLux high-throughput CCD plate imager (PerkinElmer). The 573 to 405 (Read 2 / Read 1) absorbance ratio was used to compute reaction progress.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009677714 uMActivity at 0.00204 uMActivity at 0.00323 uMActivity at 0.00612 uMActivity at 0.00969 uMActivity at 0.017 uMActivity at 0.022 uMActivity at 0.050 uMActivity at 0.067 uMActivity at 0.151 uMActivity at 0.201 uMActivity at 0.319 uMActivity at 0.516 uMActivity at 0.958 uMActivity at 1.490 uMActivity at 2.355 uMActivity at 4.463 uMActivity at 7.066 uMActivity at 13.39 uMActivity at 21.20 uMActivity at 38.03 uMActivity at 48.78 uMActivity at 109.9 uMActivity at 146.3 uMActivity at 232.8 uMActivity at 342.9 uMCompound QC
Inhibitor56.933655.28821Partial curve; partial efficacy-4.244610.9047-61.2039-5.9159-2.20 0 0 0 0 0 0 0 0 0 0-53.6877-8.0052-2.7122-15.476-5.9098-14.0508-0.4974-12.1417-12.2892-20.4756-37.3372-53.6877QC'd by ChemRoutes
Inhibitor6.153910.122510Complete curve; partial efficacy; poor fit-5.210810.5111-34.5479-24.4255-1.40 0 0 0 0 0 0 0 0 0 0-35.8733-24.9947-21.632-21.8592-24.9061-31.012-25.9926-19.9379-31.6439-35.1027-28.4537-35.8733QC'd by ChemRoutes
Inhibitor110.696244.794110Single point of activity-3.955910.5505-45.6234-0.8293-30 0 0 0 0 0 0 0 0 0 0-34.4117-5.8613-3.4569-7.9439-4.89020.41883.02491.95358.8817-9.47721.0854-34.4117QC'd by ChemRoutes
Inhibitor62.24935.329610Partial curve; partial efficacy; poor fit-4.205910.4222-36.7243-1.3947-2.40 0 0 0 0 0 0 0 0 0 0-32.4347-8.2797-3.8227-5.11877.52211.5127-3.0916-6.0045-21.43258.3897-11.6999-32.4347QC'd by ChemRoutes
Inhibitor69.047856.477810Partial curve; partial efficacy; poor fit-4.160810.558-52.61833.8594-2.40 0 0 0 0 0 0 0 0 0 0-46.465815.250913.9169-11.7902-17.706916.34612.63258.6404-11.39152.741-11.8735-46.4658QC'd by ChemRoutes
Inactive0004-5.50449.31782.5747-4.9123-15.774411.38173.7062.8695-5.751211.17465.3749-5.5044QC'd by ChemRoutes
Inactive0-4.755910.75-21.35887.540 0 0 0 0 0 0 0 0 0 0-19.8824-1.638715.16925.085115.00115.00094.27778.1232-3.2474-3.8342-8.9139-19.8824QC'd by ChemRoutes
Inactive0-5.605910.6551-5.404812.540 0 0 0 0 0 0 0 0 0 0-3.38267.123417.70428.725310.918815.4829.141815.0186-8.6706-2.638-2.0851-3.3826QC'd by ChemRoutes
Inactive0-6.860810.4235-8.539216.060941 0 0 0 0 0 0 0 0 0 0-28.957328.72176.778619.286218.0321-7.5293-5.1512-7.5284-3.865810.0685-5.1877-28.9573QC'd by ChemRoutes
Inactive0-5.355910.7592-27.66791.480640 0 0 0 0 0 0 0 0 1 0-25.55651.6478-2.7539-5.35280.383814.8319-1.5834-9.4686-9.7263-22.67638.2867-25.5565QC'd by ChemRoutes
Inactive0-4.855910.4122-18.8587-0.540 0 0 0 0 0 0 0 0 0 0-22.3822-6.2474-11.1182.12080.88075.70227.50943.0335-13.757-11.6828-3.6848-22.3822QC'd by ChemRoutes
Inactive0004-14.33940.1577-0.0619-7.3133-17.3287-7.52742.19150.2215-10.7257-13.92484.8228-14.3394QC'd by ChemRoutes
Inactive0004-23.2662-14.2265-11.735-14.7455-15.53418.38910.7359-0.9108-16.5035-8.0784-12.2269-23.2662QC'd by ChemRoutes
Inactive0004-9.88158.43510.4042-9.9889-19.318517.021-0.22638.7079-7.37620.712310.8203-9.8815QC'd by ChemRoutes
Inactive0-3.810.7208-38.73457.298341 0 0 0 0 0 0 0 0 0 0-28.6969-17.10283.6231-1.74512.885612.109514.28593.41244.336213.225-12.5835-28.6969QC'd by ChemRoutes
Inactive0-7.405910.41820-12.019840 0 0 0 0 0 0 0 0 0 1-22.8555-10.3527-6.7739-17.0998-2.94813.6637-5.19192.6381.8745-8.84272.669-22.8555QC'd by ChemRoutes
Inactive0004-2.91477.675529.6573-1.9621-3.57768.511411.45942.4557-9.9472-6.99762.3091-2.9147QC'd by ChemRoutes
Inactive00044.6666.2673-13.0838-12.1742-4.727612.401315.17725.2546-6.8644-8.36691.82624.666QC'd by ChemRoutes
Inactive0004-21.1859-9.3966-5.8928-13.2625-10.534215.961412.6298-2.6554-11.19-7.2031-5.2975-21.1859QC'd by ChemRoutes
Inactive0-3.994510.6611-39.6911-240 0 0 0 0 0 0 0 0 0 0-29.7426-1.0394-7.6256-9.1811.80061.23645.7378-4.57-11.14323.0771-16.511-29.7426QC'd by ChemRoutes
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: IP6K1-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Reagent, 3 uL of 1.3 mM ATP and 130 uM IP6 mixture in assay buffer was dispensed to a white, 1536-well assay plate.
2. Compound, 23 nL of compounds of the top two doses (57.5 uM and 19.1 uM final concentration) of the libraries were dispensed into the mixture using the Kalypsis pintool.
3. Reagent, 1 uL of 2.4 uM IP6K1 was dispensed to the assay plates.
4. Incubation, 2 hr incubation at room temperature.
5. Reagent, 2 uL of ADP-Glo reagent was added to the wells.
6. Incubation, 1 hr incubation at room temperature.
7. Reagent, 4 uL or ADP-Glo substate was added to the wells.
8. Incubation, 45 min incubation at room temperature.
9. Detection, luminescence signal was detected using the ViewLux microplate imager (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Majority of the compounds were tested at 58uM and 11uM. Percent inhibition at 58uM (Max_Response) was obtained and used for compound ranking.
2. For all inactive compounds, with Max_Response >= -25.00, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds (Max_Response < -25.00, more than 25% inhibition) a score range was given between 25 and 100. The activity score is based on the absolute value of the Max_Response.
PhenotypeAnalysis CommentActivity_ScoreMax_ResponseActivity at 0.029 uMActivity at 0.115 uMActivity at 0.144 uMActivity at 0.230 uMActivity at 0.575 uMActivity at 1.257 uMActivity at 2.059 uMActivity at 2.870 uMActivity at 3.790 uMActivity at 5.750 uMActivity at 7.911 uMActivity at 11.54 uMActivity at 17.22 uMActivity at 25.95 uMActivity at 38.35 uMActivity at 57.50 uMActivity at 85.10 uMActivity at 115.2 uMActivity at 153.0 uMActivity at 245.0 uMActivity at 288.0 uMCompound QC
Inactive0-0.963.5361-0.96QC'd by Chemdiv
Inactive0-0.9559-3.6852-0.9559QC'd by Chemdiv
Inactive0-0.9553-5.7534-0.9553QC'd by Chemdiv
Inactive0-0.9545-5.6084-0.9545QC'd by ChemRoutes
Inactive0-0.953-2.3216-0.953QC'd by Sytravon
Inactive0-0.94922.2186-0.9492QC'd by Edelris
Inactive0-0.9486-1.2758-0.9486QC'd by Chemdiv
Inactive0-0.94674.4666-0.9467QC'd by ChemRoutes
Inactive0-0.9436-8.9932-0.9436QC'd by Chemdiv
Inactive0-0.9422-1.7826-0.9422QC'd by Analyticon
Inactive0-0.9415.2115-0.941QC'd by Chemdiv
Inactive0-0.93984.3972-0.9398QC'd by Sytravon
Inactive0-0.93624.3836-0.9362QC'd by Chemdiv
Inactive0-0.92992.8643-0.9299QC'd by Sytravon
Inactive0-0.92934.8772-0.9293QC'd by Chemdiv
Inactive0-0.9286-10.0521-0.9286QC'd by Chemdiv
Inactive0-0.9253-2.1742-0.9253QC'd by Sytravon
Inactive0-0.92040.4163-0.9204QC'd by Edelris
Inactive0-0.9193-0.0183-0.9193QC'd by Analyticon
Inactive0-0.9182-0.8109-0.9182QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: MTASE-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; SMMTase Enzyme (2x) in reaction buffer, columns 1- 48.
2; Reagent; 1 uL; SAM (4x) in reaction buffer, columns 1-48.
3; Controls; 23 nL; DMSO in column 4; sinefungin in DMSO (0 uM - 40 uM) in 7-point 1:2 dilution series (n = 2) in column 2.
4; Compounds; 23 nL; Columns 5-48.
5; Reagent; 1 uL; Substrate (4x) in reaction buffer, columns 2-48.
6; Time; 20-30 min; Incubation.
7; Reagent; 1 uL; MTase-Glo reagent (5X), columns 1-48.
8; Time; 30 min; Incubation.
9; Reagent; 5 uL; MTase-Glo Detection reagent, columns 1-48.
10; Time; 30 min; Incubation, luminescence evolution.
11; Detection; Luminescence; ViewLux uHTS Microplate Imager (PerkinElmer).

NOTES (numbers refer to Sequence numbers above)
1, 2, 5. White Medium Binding Greiner 1536-well plates (Cat #789175-F, Greiner Bio-One, Monroe, NC); Reaction buffer: 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA. Evaporation was prevented by covering assay plates with metal lids containing holes to allow gas diffusion.
1. Six SMMTase were profiled: HNMT, GNMT, PNMT, COMT, NNMT, GAMT
2. The corresponding SAM cofactor concentration was used for each SMMTase: HNMT - 9.3 uM SAM; GNMT - 12.1 uM SAM; PNMT - 3.6 uM SAM; COMT - 14.5 uM SAM; NNMT 11.9 uM SAM; GAMT - 5.6 uM SAM.
3, 4. Pintool transfer
5. The corresponding substrate was used for each enzyme: HNMT - 5.3 uM Histamine; GNMT - >500 uM Glycine; PNMT - 16.2 uM Norephinephrine; COMT - 13.7 uM Norephinephrine; NNMT - 3.8 uM Nicotinamide; GAMT - 2.5 uM Guanidinoacetate.6, 8, 10. Room temperature
6. Final reaction conditions: 10 nM COMT, 5 uM SAM, 15 uM norepinephrine, 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA; refer to tables 2 and S1 for specific timing.
8. Conversion of SAH to ADP; MTase Glo Kit (Promega, Madison, WI).
10. Conversion of ADP to ATP and detection by UltraGlo luciferase; MTase Glo Kit (Promega, Madison, WI).
11. Settings: 20 s exposure, 1X binning, high gain, medium speed.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are assayed at single point activity (40 uM).
2. Active / Inactive compound calling is based on the results of the enzyme assay panel. ACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 50 and are compounds that have <= -50% max response in ANY ONE of the six enzymes. INACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 0 and are those that have >= -30% max response in ALL SIX enzymes. The remaining compounds are INCONCLUSIVE and have PUBCHEM_ACITIVITY_SCORE = 30.
COMT-Max_ResponseGAMT-Max_ResponseGNMT-Max_ResponseHNMT-Max_ResponseNNMT-Max_ResponsePNMT-Max_Response
-14.477-0.906-64.36-7.723-13.221-6.568
-97.283-96.83-99.246-99.097
-11.662-7.108-69.542-15.105-18.57-11.209
9.957-8.37-63.807-27.029-13.633-0.512
-1.3788.081-1.801-70.001-9.255-2.174
-4.184-8.838-45.186-20.976-17.93-50.762
-64.186-17.487-82.517-23.323-14.889-4.424
-28.27-13.82-44.132-13.042-22.645-61.981
-95.9186.395-70.158.26-8.601-15.867
-6.366.696-61.41910.286-22.134-20.539
2.7649.187-5.281.889-50.6463.945
5.467.241-52.1632.748-5.3684.271
18.645-5.1-85.869-4.46517.42
-33.223-8.861-69.978-8.649-22.429-13.542
-22.681-17.904-81.69-53.866-21.453-18.314
3.649-5.536-6.193-64.526-18.858-7.356
-17.938-19.922-61.7-32.188-41.884-42.419
-0.0336.8778.069-87.187-3.6082.522
66.24812.293-50.945-8.947-3.8437.458
-0.7140.817-11.379-86.711-10.789-2.627
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Center for Chemical Genomics, University of Michigan 靶标:
External ID: MScreen:TargetID_600
Protocol: C-terminally 6xHis tagged CDK2/Cyclin A complex and N-terminally Flag tagged CDC25B C473S (372-566) were expressed and purified. Proteins were incubated together at a final concentration of 125 nM each for 1 hr prior to incubation with compound for 1 hr, followed by addition of anti-6xHis europium cryptate donor beads (Cisbio) and anti-Flag XL-665 acceptor beads (Cisbio) at a final dilution of 1:350 for 1 hr. 20mM potassium fluoride was added 10 minute prior to plate reading. Assay reagents were dispensed using a multidrop liquid dispenser (Thermo Scientific) onto uncoated, black, low-volume, 384-well plates (Corning). Assay plates were quantified using an Envision plate reader (Perkin-Elmer) with excitation of the europium crytate donor at 337 nm wavelength and emission of the donor at 620 nm and emission of the XL-665 acceptor at 665 nm in 18 uL volumes. Assays were performed in a buffer containing 50 mM Tris (pH 7.5), 50 mM NaCl, 10mM MgCl2, 1mM TCEP, with addition of and 1mM ATP, 0.05% BSA, and 0.05% Tween-20 immediately prior to the start of the assay.
Comment: The activity outcome is based on a Z-score (number of standard deviations from the negative control mean) of 3 or higher on at least 50% times that the sample was screened.
For instance, if the sample was screened in n=4 runs, it would be considered active only if it had a Z-score of 3 or above in at least 2 runs.

This screen was funded by NIH grant number: R01CA181185
Z_SCORE
0.28
-0.54
-0.02
0.22
0.37
-0.81
-0.26
-0.14
-0.61
-0.44
0.29
0.22
-0.12
-0.13
0.95
-0.29
-0.37
0.17
-0.64
-0.78
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: 12hLO-f-round2
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION
1; Enzyme; 3 uL; 150 nM 12hLO enzyme solution dispensed in 1536-well Greiner black, clear bottom plates.
2; Compound; 23 nL; compounds and controls were added.
3; Incubate; 15 min; room temperature.
4; Substrate; 1 uL; 40 uM arachidonic acid (final concentration).
5; Incubate; 30 min; room temperature.
6; Reagent; 4 uL; Fe-XO solution was added to each well.
7; Incubation; 30 min; room temperature
8; Detector; absorbance; Read 1 at 405 nm absorbance using ViewLux (PerkinElmer) CCD imager.
9; Detector; absorbance; Read 2 at 573 nm absorbance using ViewLux (PerkinElmer) CCD imager.
NOTES (numbers refer to sequence above)
1; 150 nM 12hLO (final concentration) in buffer solution (25 mM Hepes, 0.01% Triton X-100, pH 7.0) was dispensed in columns 1, 2, 5-48. Column 1 is neutral (100% activity). Buffer only was dispensed in columns 3 and 4 as no enzyme negative controls. The plates were covered with metal lids with gas-exchange holes.
2; Compounds were pin transferred via a Kalypsys Pin Tool (Wako USA) in column 5 - 48. Control compound was transferred in column 2, titration of nordihydroguaiaretic acid (NDGA, Sigma-Aldrich, N5023) with top concentration of 20 mM in DMSO then 1:3 dilution in duplicate. Dilution factor of 23 nL into 4 uL final assay volume.
3; Covered assay plates were incubated for 15 min at room temperature.
4; Substrate was added to start the reaction; 40 uM arachidonic acid (Sigma-Aldrich, St. Louis, MO) was dispensed throughout the plate.
6; Chromogenic detection reagent solution (divalent iron/xylenol orange, Fe-XO) was added to each well: 200 uM xylenol orange, 300 uM ferrous ammonium sulfate prepared freshly in 50 mM sulfuric acid.
8, 9; Two absorbance readouts were obtained at 405 nm and at 573 nm using a ViewLux high-throughput CCD plate imager (PerkinElmer). The 573 to 405 (Read 2 / Read 1) absorbance ratio was used to compute reaction progress.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000767051 uMActivity at 0.0001415737 uMActivity at 0.0002841909 uMActivity at 0.0005621259 uMActivity at 0.0009699086 uMActivity at 0.00203 uMActivity at 0.00306 uMActivity at 0.00610 uMActivity at 0.00936 uMActivity at 0.020 uMActivity at 0.050 uMActivity at 0.066 uMActivity at 0.143 uMActivity at 0.255 uMActivity at 0.473 uMActivity at 0.794 uMActivity at 1.616 uMActivity at 3.555 uMActivity at 6.210 uMActivity at 12.66 uMActivity at 19.16 uMActivity at 35.99 uMActivity at 64.46 uMActivity at 124.6 uMActivity at 232.5 uMActivity at 342.9 uMCompound QC
Inhibitor1.9314106.59286Complete curve; high efficacy-5.71412.24810.9918-95.227611.3644-1.10 0 0 0 0 0 0 0 0 0 0-96.18953.070915.26477.670514.00438.075117.4543.0001-49.7114-84.7302-95.31-96.1895QC'd by NCGCChem
Inhibitor6.1078106.825283Complete curve; high efficacy-5.21411.41630.986-85.46121.3642-1.10 0 0 0 0 0 0 0 0 0 0-84.209220.193814.480623.436318.052921.787331.27312.59342.8282-32.3297-65.7574-84.2092QC'd by NCGCChem
Inhibitor15.848991.476381Complete curve; high efficacy-4.82.72020.9841-98.9177-7.4414-1.10 0 0 0 0 0 0 0 0 0 0-92.1021-9.0788-9.2047-9.8858-6.9308-5.0138-12.6976-0.6647-19.8236-44.0558-89.1961-92.1021QC'd by Analyticon
Inhibitor5.011976.53863Complete curve; partial efficacy-5.31.37230.9948-81.1129-4.5748-1.20 0 0 0 0 0 0 0 0 0 0-77.4193-1.6663-8.0529-4.2491-7.7256-13.1641-20.3102-29.9673-52.8586-67.0299-75.9994-77.4193QC'd by Analyticon
Inhibitor6.224967.217663Complete curve; partial efficacy-5.205910.942-77.3742-10.1566-1.20 0 0 0 0 0 0 0 0 0 0-72.2581-12.9831-5.8462-18.337-16.7485-11.3163-7.9828-12.1002-40.6272-63.6699-64.4969-72.2581QC'd by ChemRoutes
Inhibitor9.6802110.162242Partial curve; high efficacy-5.01411.66040.9887-90.832119.3301-2.10 0 0 0 0 0 0 0 0 0 0-84.642621.3118.385710.442518.69618.319822.746721.51915.2621-22.851-62.2581-84.6426QC'd by Enamine
Inhibitor21.6712104.359341Partial curve; high efficacy-4.66411.55790.9529-83.459620.8997-2.10 0 0 0 0 0 0 0 0 0 0-69.549618.665923.682521.859121.288824.776626.448524.1111.12078.872-22.5267-69.5496QC'd by NCGCChem
Inhibitor61.538963.120921Partial curve; partial efficacy-4.210810.9237-71.8651-8.7442-2.20 0 0 0 0 0 0 0 0 0 0-54.4432-18.5921-9.1263-5.7816-2.9999-3.9852-11.1061-10.9872-12.9659-23.0007-33.5733-54.4432QC'd by ChemRoutes
Inhibitor69.047838.238421Partial curve; partial efficacy-4.160810.8756-45.2266-6.9882-2.20 0 0 0 0 0 0 0 0 0 0-35.8942-11.7589-5.303-8.9112-4.1569-5.0635-7.3568-5.4239-14.383-13.6471-17.5503-35.8942QC'd by ChemRoutes
Inhibitor3.981141.441221Complete curve; partial efficacy-5.40.50.8845-30.941210.5-1.20 0 0 0 0 0 0 0 0 0 0-22.4517.38051.22168.9658-5.359-7.5643-3.0362-7.2913-11.2256-16.8761-21.3891-22.451QC'd by Chemdiv
Inhibitor8.912572.156521Partial curve; partial efficacy-5.050.40.888-51.066921.0895-2.20 0 0 0 0 0 0 0 0 0 0-38.143514.804212.47939.1585-0.4614-4.0272-7.172-7.4528-6.2212-11.9084-22.761-38.1435QC'd by Chemdiv
Inhibitor24.315568.399720Partial curve; partial efficacy-4.61412.33320.9198-53.26815.1318-2.20 0 0 0 0 0 0 0 0 0 0-53.92977.483918.464319.249214.543112.077922.387918.980113.54383.5117-2.6741-53.9297QC'd by NCGCChem
Inhibitor49.446250.159420Partial curve; partial efficacy-4.305910.8388-36.868713.2907-2.20 0 0 0 0 0 0 0 0 0 0-26.644515.420715.66097.799915.1822.308811.14094.66835.97132.2831-1.2217-26.6445QC'd by ChemRoutes
Inhibitor21.671281.896410Partial curve; partial efficacy; poor fit-4.66412.40640.9781-69.855212.0413-2.40 0 1 0 0 0 0 0 0 0 0-64.94816.369215.2577-38.975611.643711.812915.82519.290215.87772.2113-20.2084-64.9481QC'd by NCGCChem
Inhibitor10Single point of activity00-3-32.901-18.1987-14.0529-14.167-10.5998-2.5897-12.5459-13.7461-20.8757-6.457-19.942-32.901QC'd by ChemRoutes
Inhibitor10Single point of activity00-3-35.8003-8.845-20.8688-5.804-9.3981.2088-19.4574-2.5178-11.7221-18.1149-26.6328-35.8003QC'd by ChemRoutes
Inhibitor77.472947.35710Partial curve; partial efficacy; poor fit-4.110810.7046-39.46027.8968-2.40 0 0 0 0 0 0 0 0 0 0-32.88357.665214.41295.1392.2509-2.23686.86799.40927.281616.0847-10.7248-32.8835QC'd by ChemRoutes
Inhibitor113.619470.362310Partial curve; partial efficacy; poor fit-3.944510.7164-76.5743-6.212-2.40 0 0 0 0 0 0 0 0 0 0-63.8119-18.1927-12.79753.3085-2.9533-9.30050.4204-14.3528-12.5891-1.8745-19.6513-63.8119QC'd by ChemRoutes
Inhibitor137.768547.712810Single point of activity-3.860810.4749-44.65623.0565-30 0 0 0 0 0 0 0 0 0 0-33.1411-1.2821-2.03752.0548-4.5034-0.3688-5.232415.72882.606912.79671.1953-33.1411QC'd by ChemRoutes
Inhibitor12.420325.421210Partial curve; partial efficacy; poor fit-4.905910.7994-28.4212-3-2.40 0 0 0 0 0 0 0 0 0 0-30.351-4.1561-2.5178-9.43491.4257-1.50721.7076-11.4956-10.9066-16.6914-16.5994-30.351QC'd by ChemRoutes
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF003
Protocol: NIH 3T3 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 400 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.461 uMActivity at 0.922 uMActivity at 1.931 uMActivity at 2.760 uMActivity at 3.496 uMActivity at 4.617 uMActivity at 5.750 uMActivity at 9.220 uMActivity at 11.47 uMActivity at 13.80 uMActivity at 17.43 uMActivity at 23.06 uMActivity at 36.90 uMActivity at 46.10 uMActivity at 57.33 uMActivity at 72.74 uMActivity at 96.71 uMActivity at 138.0 uMActivity at 174.3 uMActivity at 230.0 uMActivity at 278.6 uMActivity at 369.0 uMActivity at 461.0 uMCompound QC
Inactive0-3.94.95490.95-15.54262.540 0 0 0-14.61882.1650.75391.4439-14.6188QC'd by ChemRoutes
Inactive000401.7485000QC'd by ChemRoutes
Inactive0004-3.7855-3.5922-7.5877-2.927-3.7855QC'd by ChemRoutes
Inactive0004-6.8753-5.1403-7.4134-10.3163-6.8753QC'd by ChemRoutes
Inactive0004-2.50691.03281.2450-2.5069QC'd by ChemRoutes
Inhibitor10041.194310Partial curve; partial efficacy; poor fit-44.95490.9943-39.21791.9764-2.40 0 0 0-37.47193.0010-13.5769-37.4719QC'd by ChemRoutes
Inactive0-3.954.50450.9558-25.984-5.082640 0 0 0-24.1533-2.9855-7.6452-11.0914-24.1533QC'd by ChemRoutes
Inactive0-4.253.19250.9991-8.9359240 0 0 0-8.27992.01932.1472-5.1633-8.2799QC'd by ChemRoutes
Inactive0004-2.193000-2.193QC'd by ChemRoutes
Inactive0-4.34.50450.923-19.8493-140 0 0 0-19.8744-4.61932.2351-15.9954-19.8744QC'd by ChemRoutes
Inhibitor112.201832.301310Partial curve; partial efficacy; poor fit-3.954.0950.963-41.5571-9.2558-2.40 0 0 0-37.7694-5.6298-12.135-19.5297-37.7694QC'd by ChemRoutes
Inactive0-4.050.9310.9337-34.8911-7.210540 0 0 0-27.4092-7.6754-13.9036-18.5729-27.4092QC'd by ChemRoutes
Inhibitor31.622831.690810Partial curve; partial efficacy; poor fit-4.50.910.9986-32.8263-1.1355-2.40 0 0 0-24.4385-3.4462-9.2264-19.2308-24.4385QC'd by ChemRoutes
Inactive0004-5.66252.442300-5.6625QC'd by ChemRoutes
Inactive0004-7.97580.46781.75890-7.9758QC'd by ChemRoutes
Inactive0004-16.0073-11.1361-9.8129-11.4494-16.0073QC'd by ChemRoutes
Inactive0004-13.6557-5.3177-4.6644-7.6669-13.6557QC'd by ChemRoutes
Inactive0004-6.140403.55822.1342-6.1404QC'd by ChemRoutes
Inactive00040.08742.8196000.0874QC'd by ChemRoutes
Inactive0-52.63840.9997-27.5319-0.889440 0 0 0-27.1099-1.1579-12.96-27.0152-27.1099QC'd by ChemRoutes
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF002
Protocol: HEK 293 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 250 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.575 uMActivity at 1.150 uMActivity at 2.307 uMActivity at 3.450 uMActivity at 4.600 uMActivity at 5.764 uMActivity at 11.50 uMActivity at 13.80 uMActivity at 17.20 uMActivity at 23.00 uMActivity at 28.77 uMActivity at 46.00 uMActivity at 57.50 uMActivity at 69.00 uMActivity at 86.20 uMActivity at 115.3 uMActivity at 172.0 uMActivity at 230.0 uMActivity at 287.0 uMActivity at 345.0 uMActivity at 460.0 uMActivity at 575.0 uMCompound QC
Inactive0004-0.95160-0.7079-1.1451-0.9516QC'd by Chemdiv
Inhibitor89.125160.132910Single point of activity-4.054.95490.963-54.76215.3708-30 0 0 0-41.6698010.9137-0.6944-41.6698QC'd by Chemdiv
Inhibitor17.7828120.027810Complete curve; high efficacy; poor fit-4.751.66040.9958-116.80123.2266-1.30 0 0 0-107.55180-36.673-106.1477-107.5518QC'd by Chemdiv
Inactive0-5.454.95490.945-7.05756.540 0 0 0-5.21064.9971-8.3812-8.2138-5.2106QC'd by Chemdiv
Inhibitor89.125131.820310Partial curve; partial efficacy; poor fit-4.053.1320.8166-42.2203-10.4001-2.40 0 0 0-32.6836-16.8589-5.3334-15.212-32.6836QC'd by Chemdiv
Inactive0-5.151.44870.913518.5-3.540 0 0 020.8168011.433613.992320.8168QC'd by Chemdiv
Inhibitor44.668496.898910Partial curve; high efficacy; poor fit-4.351.92820.9969-96.54130.3576-2.30 0 0 0-84.68531.7383-8.5326-57.5252-84.6853QC'd by Chemdiv
Inhibitor79.432885.755110Partial curve; partial efficacy; poor fit-4.13.1320.9942-83.14052.6146-2.40 0 0 0-62.98525.86890-20.7942-62.9852QC'd by Chemdiv
Inhibitor56.2341112.911710Partial curve; high efficacy; poor fit-4.251.82650.9409-113.9646-1.0529-2.30 0 0 0-99.96895.3202-17.4562-48.105-99.9689QC'd by Chemdiv
Inactive0-4.64.95490.8281-2.8855840 0 0 0-0.80515.280510.451-4.9046-0.8051QC'd by Chemdiv
Inhibitor50.118748.992610Partial curve; partial efficacy; poor fit-4.32.72020.9808-43.48925.5034-2.40 0 0 0-42.63642.54937.4317-22.781-42.6364QC'd by Chemdiv
Inhibitor79.432895.572310Single point of activity-4.14.50450.9949-87.24848.3238-30 0 0 0-72.15794.700311.3653-9.5791-72.1579QC'd by Chemdiv
Inhibitor50.118772.371710Partial curve; partial efficacy; poor fit-4.32.40640.9764-71.9230.4487-2.40 0 0 0-70.51270-2.201-36.5816-70.5127QC'd by Chemdiv
Inactive0004-4.8558-1.4812-1.08484.2597-4.8558QC'd by Chemdiv
Inhibitor56.234161.481410Partial curve; partial efficacy; poor fit-4.252.25260.9495-53.91237.569-2.40 0 0 0-52.85528.52534.1128-18.3695-52.8552QC'd by Chemdiv
Inactive0-5.050.96410.9159-8.76771640 0 0 0-8.973111.4390.6258-1.9481-8.9731QC'd by Chemdiv
Inactive0-4.154.0950.74-1.923711.540 0 0 0-0.35317.456915.61337.1718-0.3531QC'd by Chemdiv
Inhibitor44.668480.451410Partial curve; partial efficacy; poor fit-4.351.37230.9622-61.134319.3171-2.40 0 0 0-50.945220.64043.9751-22.0296-50.9452QC'd by Chemdiv
Inhibitor50.1187102.898510Partial curve; high efficacy; poor fit-4.32.40640.96-94.43278.4658-2.30 0 0 0-92.5811013.2413-45.2039-92.5811QC'd by Chemdiv
Inhibitor50.118796.811910Partial curve; high efficacy; poor fit-4.32.72020.9709-90.71516.0968-2.30 0 0 0-88.9364-1.777812.6768-49.603-88.9364QC'd by Chemdiv